Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
BSE: 543350 | NSE: VIJAYA | Hospital & Healthcare Services | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Vijaya Diagnostic Centre Ltd is a good quality company.
The key valuation ratios of Vijaya Diagnostic Centre Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Vijaya Diagnostic Centre Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 0% | 0% | 0% | 0% | 0% | 22.1% | 25.9% | 28.3% | 29% | 19.5% | - |
| Value Creation Index ⓘ | NA | NA | NA | NA | NA | 0.6 | 0.9 | 1.1 | 1.1 | 0.4 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 0 | 0 | 0 | 0 | 0 | 293 | 339 | 377 | 462 | 459 | 514 |
| Sales YoY Gr. | - | NA | NA | NA | NA | NA | 15.8% | 11.2% | 22.7% | -0.7% | - |
| Adj EPS ⓘ | 0 | 0 | 0 | 0 | 0 | 4.5 | 6 | 8.3 | 10.7 | 8.3 | 11 |
| YoY Gr. | - | NA | NA | NA | NA | NA | 34.2% | 37.6% | 29.5% | -22.6% | - |
| BVPS (₹) ⓘ | 0 | 0 | 0 | 0 | 0 | 20.1 | 26.9 | 35.1 | 45.7 | 53.2 | 60.9 |
| Adj Net Profit ⓘ | 0 | 0 | 0 | 0 | 0 | 45.6 | 61.3 | 84.4 | 109 | 84.6 | 113 |
| Cash Flow from Ops. ⓘ | 0 | 0 | 0 | 0 | 0 | 90.5 | 106 | 130 | 158 | 165 | - |
| Debt/CF from Ops. ⓘ | 0 | 0 | 0 | 0 | 0 | 0.5 | 0.3 | 0 | 0 | 0 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | NA | 10.7% | -0.7% | ||||
| Adj EPS ⓘ | NA | NA | 11.3% | -22.6% | ||||
| BVPSⓘ | NA | NA | 25.5% | 16.3% | ||||
| Share Price | - | - | - | 80.3% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 0 | 0 | 0 | 0 | 0 | 22 | 25.4 | 26.6 | 26.4 | 16.7 | 19.3 |
| Op. Profit Mgn % ⓘ | 0 | 0 | 0 | 0 | 0 | 37 | 39.1 | 44.1 | 44.1 | 39.6 | 40.3 |
| Net Profit Mgn % ⓘ | 0 | 0 | 0 | 0 | 0 | 15.7 | 18.1 | 22.6 | 23.8 | 18.5 | 22 |
| Debt to Equity ⓘ | 0 | 0 | 0 | 0 | 0 | 0.2 | 0.1 | 0 | 0 | 0 | - |
| Working Cap Days ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 26 | 30 | 35 | 36 | 103 |
| Cash Conv. Cycle ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | -32 | -31 | -25 | -27 | 78 |
Sales growth is growing at healthy rate in last 3 years 10.67%
Net Profit is growing at healthy rate in last 3 years 11.32%
Sales growth is good in last 4 quarters at 13.10%
Return on Equity has declined versus last 3 years average to 19.30%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 10.9 | 11 |
| TTM Sales (₹ Cr.) | 502 | 514 |
| BVPS (₹.) ⓘ | 60.8 | 60.9 |
| Reserves (₹ Cr.) ⓘ | 612 | 613 |
| P/BV ⓘ | 11.26 | 11.24 |
| PE ⓘ | 63.14 | 62.10 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 349.50 / 718.90 |
| All Time Low / High (₹) | 292.00 / 718.90 |
| Market Cap (₹ Cr.) | 7,009 |
| Equity (₹ Cr.) | 10.2 |
| Face Value (₹) | 1 |
| Industry PE ⓘ | 86.1 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|---|
| Sales | 293 | 339 | 377 | 462 | 459 |
| Operating Expenses ⓘ | 184 | 206 | 211 | 259 | 277 |
| Manufacturing Costs | 22 | 25 | 33 | 36 | 44 |
| Material Costs | 40 | 44 | 57 | 71 | 59 |
| Employee Cost | 54 | 62 | 57 | 71 | 78 |
| Other Costs ⓘ | 68 | 75 | 63 | 80 | 96 |
| Operating Profit ⓘ | 108 | 133 | 166 | 204 | 182 |
| Operating Profit Margin (%) | 37.0% | 39.1% | 44.1% | 44.1% | 39.6% |
| Other Income ⓘ | 10 | 15 | 12 | 13 | 14 |
| Interest ⓘ | 14 | 15 | 15 | 16 | 21 |
| Depreciation ⓘ | 40 | 49 | 50 | 53 | 62 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 65 | 83 | 112 | 147 | 114 |
| Tax ⓘ | 19 | 21 | 27 | 37 | 28 |
| Profit After Tax | 46 | 63 | 85 | 111 | 85 |
| PAT Margin (%) | 15.8% | 18.4% | 22.6% | 23.9% | 18.6% |
| Adjusted EPS (₹) | 4.5 | 6.1 | 8.3 | 10.8 | 8.3 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 9% | 12% |
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 207 | 275 | 358 | 466 | 543 | |||||
| Share Capital ⓘ | 7 | 5 | 5 | 10 | 10 | |||||
| Reserves ⓘ | 200 | 270 | 354 | 456 | 533 | |||||
| Minority Interest | -0 | -0 | 0 | 1 | 2 | |||||
| Debt | 33 | 23 | 4 | 1 | 0 | |||||
| Long Term Debt | 32 | 22 | 3 | 0 | 0 | |||||
| Short Term Debt | 2 | 1 | 1 | 1 | 0 | |||||
| Trade Payables | 22 | 22 | 22 | 22 | 28 | |||||
| Others Liabilities ⓘ | 143 | 161 | 150 | 215 | 273 | |||||
| Total Liabilities ⓘ | 405 | 481 | 535 | 705 | 845 | |||||
Fixed Assets | ||||||||||
| Gross Block | 349 | 392 | 437 | 589 | 800 | |||||
| Accumulated Depreciation | 89 | 121 | 169 | 219 | 276 | |||||
| Net Fixed Assetsⓘ | 259 | 272 | 268 | 370 | 524 | |||||
| CWIP ⓘ | 3 | 10 | 9 | 34 | 28 | |||||
| Investmentsⓘ | 69 | 55 | 28 | 54 | 139 | |||||
| Inventories | 2 | 3 | 3 | 4 | 2 | |||||
| Trade Receivables | 9 | 8 | 7 | 10 | 9 | |||||
| Cash Equivalents | 53 | 118 | 194 | 192 | 116 | |||||
| Others Assetsⓘ | 10 | 16 | 27 | 39 | 27 | |||||
| Total Assets ⓘ | 405 | 481 | 535 | 705 | 845 | |||||
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 91 | 106 | 130 | 158 | 165 |
| PBT ⓘ | 65 | 83 | 112 | 147 | 114 |
| Adjustment ⓘ | 43 | 49 | 53 | 57 | 68 |
| Changes in Working Capital ⓘ | 1 | -3 | -5 | -7 | 9 |
| Tax Paid ⓘ | -19 | -23 | -31 | -40 | -26 |
| Cash Flow From Investing Activity ⓘ | -90 | -31 | -130 | -123 | -110 |
| Capex | -59 | -37 | -31 | -121 | -125 |
| Net Investments | -31 | 1 | -103 | -13 | 9 |
| Others ⓘ | 1 | 6 | 5 | 11 | 6 |
| Cash Flow From Financing Activityⓘ | -7 | -30 | -49 | -31 | -42 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 0 | 1 |
| Net Proceeds from Borrowing ⓘ | 7 | -9 | -28 | -3 | 0 |
| Interest Paid ⓘ | -3 | -3 | -1 | -2 | 0 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | -10 |
| Others ⓘ | -12 | -17 | -19 | -25 | -33 |
| Net Cash Flow ⓘ | -6 | 46 | -49 | 4 | 13 |
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 22.58 | 26.07 | 26.91 | 26.85 | 16.89 | |||||
| ROCE (%) | 31.56 | 35.47 | 37.97 | 39.37 | 26.53 | |||||
| Asset Turnover Ratio | 0.72 | 0.76 | 0.74 | 0.75 | 0.59 | |||||
| PAT to CFO Conversion(x) | 1.98 | 1.68 | 1.53 | 1.42 | 1.94 | Working Capital Days | ||||
| Receivable Days | 11 | 9 | 7 | 7 | 8 | |||||
| Inventory Days | 3 | 3 | 3 | 3 | 3 | |||||
| Payable Days | 196 | 181 | 140 | 112 | 153 | |||||
The company is the largest integrated diagnostic chain in southern India, by operating revenue, and also one of the fastest-growing diagnostic chain by revenue for fiscal year 2020. It offer a one-stop solution for pathology and radiology testing services to its customers through its extensive operational network, which consists of 81 diagnostic centres and 11 reference laboratories across 13 cities and towns in the states of Telangana and Andhra Pradesh and in the National Capital Region and Kolkata as on June 30, 2021.
The company offers a comprehensive range of approximately 740 routine and 870 specialized pathology tests and approximately 220 basic and 320 advanced radiology tests that cover a range of specialties and disciplines, as of June 30, 2021. Its test menu includes pathology tests ranging from basic biochemistry and clinical pathology to cytogenetics and high-end molecular diagnostic tests, and radiology tests ranging from basic echocardiograms, X-rays and ultrasounds to advanced radiology tests including computerised tomography (CT) scans, magnetic resonance imaging (MRI) scans, single photon emission computed tomography (SPECT) and advanced positron emission tomography CT (PET CT).
It also offer a broad spectrum of health and wellness packages to its customers as per their requirements. The company focus on a customer centric approach to enhance the overall quality of its services for optimal customer satisfaction. For convenience of its customers, it provide value-added services such as home collection of specimens, house calls and various delivery or access modes (i.e., at diagnostic centres, SMS, email and web portal) for test reports. Several factors, including the strength of its brand, integrated services model, quality of its diagnostic services, center infrastructure and customer experience, convenience of its operational network and home collection in its core geographies are important differentiating factors in customers choosing it as their preferred diagnostic service provider, which helps it in retaining its customers, and sets it apart from its competitors.
Business area of the company
The company is one of the fastest-growing diagnostic chains in Southern India. It offers a one-stop solution for pathology and radiology testing services.
Awards, accreditations and recognitions
Major events and milestones
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
